What question did this study set out to answer?

The study aims to examine survival trends in acute myeloid leukemia before and after venetoclax approval.

December 8, 2025BloodOpen Access

Acute myeloid leukemia during the venetoclax era: Trends in survival across demographic and socioeconomic groups.

View Full Paper

Ask AI

Bookmark

Authors

This analysis shows improved survival with venetoclax in AML, highlighting disparities in outcomes by marital status and socioeconomic factors.

The study aims to examine survival trends in acute myeloid leukemia before and after venetoclax approval.
Utilized SEER database across 17 registries to analyze AML patients diagnosed from 2016-2021
Stratified patients by demographic factors (race, marital status, age) and socioeconomic factors (urban-rural setting)
Compared 3-year overall survival between pre-venetoclax and post-venetoclax cohorts using Kaplan Meier analysis and statistical tests
Total of 12,243 AML patients were included; 4,947 pre-venetoclax and 7,296 post-venetoclax
Overall survival improved from 31.6% (pre-venetoclax) to 34.7% (post-venetoclax)
Significant survival improvement observed in non-Hispanic white patients and married individuals
Young patients (<25 years) showed the highest overall survival rates over the study periods
No significant overall survival changes noted between urban and rural settings

Barboza et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

This analysis shows improved survival with venetoclax in AML, highlighting disparities in outcomes by marital status and socioeconomic factors.